-
Something wrong with this record ?
Identifying Biomarkers for Remyelination and Recovery in Multiple Sclerosis: A Measure of Progress
VAG. Ricigliano, S. Marenna, S. Borrelli, V. Camera, E. Carnero Contentti, N. Szejko, C. Bakirtzis, S. Gluscevic, S. Samadzadeh, HP. Hartung, K. Selmaj, B. Stankoff, G. Comi, . Ecf Young Investigators/Fellows Initiative
Status not-indexed Language English Country Switzerland
Document type Journal Article, Review
NLK
Directory of Open Access Journals
from 2013
PubMed Central
from 2013
Europe PubMed Central
from 2013
ProQuest Central
from 2013-01-01
Open Access Digital Library
from 2013-01-01
ROAD: Directory of Open Access Scholarly Resources
from 2013
- Publication type
- Journal Article MeSH
- Review MeSH
Background: Multiple sclerosis (MS) pathology is characterized by acute and chronic inflammation, demyelination, axonal injury, and neurodegeneration. After decades of research into MS-related degeneration, recent efforts have shifted toward recovery and the prevention of further damage. A key area of focus is the remyelination process, where researchers are studying the effects of pharmacotherapy on myelin repair mechanisms. Multiple compounds are being tested for their potential to foster remyelination in different clinical settings through the application of less or more complex techniques to assess their efficacy. Objective: To review current methods and biomarkers to track myelin regeneration and recovery over time in people with MS (PwMS), with potential implications for promyelinating drug testing. Methods: Narrative review, based on a selection of PubMed articles discussing techniques to measure in vivo myelin repair and functional recovery in PwMS. Results: Non-invasive tools, such as structural Magnetic Resonance Imaging (MRI) and Positron Emission Tomography (PET), are being implemented to track myelin repair, while other techniques like evoked potentials, functional MRI, and digital markers allow the assessment of functional recovery. These methods, alone or in combination, have been employed to obtain precise biomarkers of remyelination and recovery in various clinical trials on MS. Conclusions: Combining different techniques to identify myelin restoration in MS could yield novel biomarkers, enhancing the accuracy of clinical trial outcomes for remyelinating therapies in PwMS.
Brain and Mind Center University of Sydney Sydney 2050 Australia
Department of Bioethics Medical University of Warsaw 02 091 Warsaw Poland
Department of Clinical Neurosciences University of Calgary Calgary AB T2N 1N4 Canada
Department of Neurology Medical Faculty Heinrich Heine University 40225 Düsseldorf Germany
Department of Neurology Palacky University Olomouc 779 00 Olomouc Czech Republic
Department of Neurology University of Warmia and Mazury 10 719 Olsztyn Poland
Department of Neurorehabilitation Sciences Casa di Cura Igea 20129 Milan Italy
Department of Neuroscience Biomedicine and Movement Science University of Verona 37129 Verona Italy
Neuroimmunology Unit Department of Neurosciences Hospital Alemán Buenos Aires C1425FQB Argentina
Neurology Clinic Clinical Centre of Montenegro 81000 Podgorica Montenegro
Neurology Department Pitié Salpêtrière Hospital APHP 75013 Paris France
Neurology Unit GHNE Paris Saclay Hospital 91400 Orsay France
Nuffield Departement of Clinical Neuroscience University of Oxford Oxford OX1 2JD UK
Paris Brain Institute ICM CNRS Inserm Sorbonne Université 75005 Paris France
References provided by Crossref.org
- 000
- 00000naa a2200000 a 4500
- 001
- bmc25008475
- 003
- CZ-PrNML
- 005
- 20250422095743.0
- 007
- ta
- 008
- 250408s2025 sz f 000 0|eng||
- 009
- AR
- 024 7_
- $a 10.3390/biomedicines13020357 $2 doi
- 035 __
- $a (PubMed)40002770
- 040 __
- $a ABA008 $b cze $d ABA008 $e AACR2
- 041 0_
- $a eng
- 044 __
- $a sz
- 100 1_
- $a Ricigliano, Vito A G $u Neurology Department, Pitié-Salpêtrière Hospital, APHP, 75013 Paris, France $u Neurology Unit, GHNE-Paris Saclay Hospital, 91400 Orsay, France $1 https://orcid.org/0000000288603548
- 245 10
- $a Identifying Biomarkers for Remyelination and Recovery in Multiple Sclerosis: A Measure of Progress / $c VAG. Ricigliano, S. Marenna, S. Borrelli, V. Camera, E. Carnero Contentti, N. Szejko, C. Bakirtzis, S. Gluscevic, S. Samadzadeh, HP. Hartung, K. Selmaj, B. Stankoff, G. Comi, . Ecf Young Investigators/Fellows Initiative
- 520 9_
- $a Background: Multiple sclerosis (MS) pathology is characterized by acute and chronic inflammation, demyelination, axonal injury, and neurodegeneration. After decades of research into MS-related degeneration, recent efforts have shifted toward recovery and the prevention of further damage. A key area of focus is the remyelination process, where researchers are studying the effects of pharmacotherapy on myelin repair mechanisms. Multiple compounds are being tested for their potential to foster remyelination in different clinical settings through the application of less or more complex techniques to assess their efficacy. Objective: To review current methods and biomarkers to track myelin regeneration and recovery over time in people with MS (PwMS), with potential implications for promyelinating drug testing. Methods: Narrative review, based on a selection of PubMed articles discussing techniques to measure in vivo myelin repair and functional recovery in PwMS. Results: Non-invasive tools, such as structural Magnetic Resonance Imaging (MRI) and Positron Emission Tomography (PET), are being implemented to track myelin repair, while other techniques like evoked potentials, functional MRI, and digital markers allow the assessment of functional recovery. These methods, alone or in combination, have been employed to obtain precise biomarkers of remyelination and recovery in various clinical trials on MS. Conclusions: Combining different techniques to identify myelin restoration in MS could yield novel biomarkers, enhancing the accuracy of clinical trial outcomes for remyelinating therapies in PwMS.
- 590 __
- $a NEINDEXOVÁNO
- 655 _2
- $a časopisecké články $7 D016428
- 655 _2
- $a přehledy $7 D016454
- 700 1_
- $a Marenna, Silvia $u Experimental Neurophysiology Unit, Institute of Experimental Neurology (INSPE), IRCCS-San Raffaele Scientific Institute, Università Vita-Salute San Raffaele, 20132 Milan, Italy
- 700 1_
- $a Borrelli, Serena $u Neuroinflammation Imaging Laboratory (NIL), Institute of NeuroScience, Université Catholique de Louvain, 1348 Brussels, Belgium $u Department of Neurology, Hôpital Erasme, Hôpital Universitaire de Bruxelles, Université Libre de Bruxelles, 1070 Brussels, Belgium $1 https://orcid.org/0000000231861562
- 700 1_
- $a Camera, Valentina $u Nuffield Departement of Clinical Neuroscience, University of Oxford, Oxford OX1 2JD, UK $u Department of Neuroscience, Biomedicine and Movement Science, University of Verona, 37129 Verona, Italy $1 https://orcid.org/0000000249259000
- 700 1_
- $a Carnero Contentti, Edgar $u Neuroimmunology Unit, Department of Neurosciences, Hospital Alemán, Buenos Aires C1425FQB, Argentina $1 https://orcid.org/0000000174355726
- 700 1_
- $a Szejko, Natalia $u Department of Clinical Neurosciences, University of Calgary, Calgary, AB T2N 1N4, Canada $u Department of Bioethics, Medical University of Warsaw, 02-091 Warsaw, Poland $1 https://orcid.org/0000000161609221
- 700 1_
- $a Bakirtzis, Christos $u Multiple Sclerosis Center, Second Department of Neurology, Aristotle University of Thessaloniki, 541 24 Thessaloniki, Greece $1 https://orcid.org/0000000247373707
- 700 1_
- $a Gluscevic, Sanja $u Neurology Clinic, Clinical Centre of Montenegro, 81000 Podgorica, Montenegro
- 700 1_
- $a Samadzadeh, Sara $u Experimental and Clinical Research Center, Charité-Universitätsmedizin Berlin, Corporate Member of Freie Universität Berlin and Humboldt-Universität zu Berlin, 12203 Berlin, Germany $u Institute of Regional Health Research and, Institute of Molecular Medicine, University of Southern Denmark, 5230 Odense, Denmark $u The Center for Neurological Research, Department of Neurology, Næstved-Slagelse-Ringsted Hospitals, 4200 Slagelse, Denmark $1 https://orcid.org/0000000335931852
- 700 1_
- $a Hartung, Hans-Peter $u Brain and Mind Center, University of Sydney, Sydney 2050, Australia $u Department of Neurology, Palacky University Olomouc, 779 00 Olomouc, Czech Republic $u Department of Neurology, Medical Faculty, Heinrich-Heine University, 40225 Düsseldorf, Germany
- 700 1_
- $a Selmaj, Krzysztof $u Department of Neurology, University of Warmia & Mazury, 10-719 Olsztyn, Poland
- 700 1_
- $a Stankoff, Bruno $u Neurology Department, Pitié-Salpêtrière Hospital, APHP, 75013 Paris, France $u Paris Brain Institute, ICM, CNRS, Inserm, Sorbonne Université, 75005 Paris, France
- 700 1_
- $a Comi, Giancarlo $u Department of Neurorehabilitation Sciences, Casa di Cura Igea, 20129 Milan, Italy
- 700 1_
- $a Ecf Young Investigators/Fellows Initiative,
- 773 0_
- $w MED00205373 $t Biomedicines $x 2227-9059 $g Roč. 13, č. 2 (2025)
- 856 41
- $u https://pubmed.ncbi.nlm.nih.gov/40002770 $y Pubmed
- 910 __
- $a ABA008 $b sig $c sign $y - $z 0
- 990 __
- $a 20250408 $b ABA008
- 991 __
- $a 20250422095744 $b ABA008
- 999 __
- $a ok $b bmc $g 2306387 $s 1245550
- BAS __
- $a 3
- BAS __
- $a PreBMC-PubMed-not-MEDLINE
- BMC __
- $a 2025 $b 13 $c 2 $e 20250204 $i 2227-9059 $m Biomedicines $n Biomedicines $x MED00205373
- LZP __
- $a Pubmed-20250408
